Researchers at Washington University School of Medicine in St Louis have found that when they kept sugar away from critical immune cells called T cells, the cells no longer produced interferon gamma, an inflammatory compound important for fighting tumours and some kinds of infection.
"T cells can get into tumours, but unfortunately they are often ineffective at killing the cancer cells," said Erika Pearce, assistant professor of pathology and immunology.
"Lack of the ability to make interferon gamma could be one reason why they fail to kill tumours. By understanding more about how sugar metabolism affects interferon production, we may be able to develop treatments that fight tumours by enhancing T cell function," Pearce said.
Like most cells, T cells can make energy either by using an efficient process called oxidative phosphorylation or a less efficient pathway called aerobic glycolysis.
Cells normally make most of their energy via oxidative phosphorylation, but they need oxygen to do so. If oxygen runs short, most cells switch to aerobic glycolysis. Low sugar levels can force cells to use oxidative phosphorylation for their energy.
Scientists aren't sure why, but many cells, including T cells, switch to aerobic glycolysis when they need to reproduce rapidly.
For the new study, Chih-Hao Chang, a postdoctoral researcher in the Pearce lab and first author of the study, set up a system that allowed him to control the resources available to T cells in test tubes.
When the scientists put T cells in a dish with cancer cells, which regularly consume large amounts of sugar, the T cells' ability to make inflammatory compounds was impaired. But when the researchers gave sugar directly to the T cells, production of those inflammatory compounds doubled.
"T cells often can go everywhere - tumours, inflammation, infections - but sometimes they don't do anything. If we can confirm that this same switch is involved in these failures in the body, we might be able to find a way to put the fight back into those T cells," Pearce added.
The study was published in the journal Cell.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
